Merry Christmas? Four US FDA approvals and a CRL
This article was originally published in Scrip
Executive Summary
The US FDA took action on five new drug and biologic license applications (NDAs and BLAs) during the two days before Christmas, approving four products or label updates and rejecting one combination therapy.